BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

54.68 1.37 −2.44%
Market cap
$10.9B
P/E
144×
Fwd P/E
16.1×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

9.07% 5.94% 4.48% 1.18%
Piotroski F-Score
8 5 4 3
ROA
7.20% 4.79% 3.42% 0.76%
ROIC
7.43% 5.00% 3.64% 0.97%
Return on Tangible Assets
12.71% 8.41% 5.63% 2.21%
Average Days of Receivables
93.23 102.91 101.76 113.69
Free Cash Flow per Share
4.30 3.74 3.98 3.75
Free Cash Flow
825.79 717.02 767.06 724.81
Other line items

Show all line items

Columns are period end dates